featured
Effect of Hydrocortisone on Mortality and Organ Support in Patients With Severe COVID-19
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
- Association Between Use of Systemic Corticosteroids and Mortality in Critically Ill Patients With COVID-19
- Effect of Hydrocortisone on 21-Day Mortality or Respiratory Support Among Critically Ill Patients With COVID-19
- Effect of Dexamethasone on Days Alive and Ventilator–Free in Patients With Moderate or Severe ARDS and COVID-19
Disclosure statements are available on the authors' profiles:
JAMA: The Journal of the American Medical Association
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Effect of Hydrocortisone on Mortality and Organ Support in Patients With Severe COVID-19: The REMAP-CAP COVID-19 Corticosteroid Domain Randomized Clinical Trial
JAMA 2020 Sep 02;[EPub Ahead of Print], DC Angus, L Derde, F Al-Beidh, D Annane, Y Arabi, A Beane, W van Bentum-Puijk, L Berry, Z Bhimani, M Bonten, C Bradbury, F Brunkhorst, M Buxton, A Buzgau, AC Cheng, M de Jong, M Detry, L Estcourt, M Fitzgerald, H Goossens, C Green, R Haniffa, AM Higgins, C Horvat, SJ Hullegie, P Kruger, F Lamontagne, PR Lawler, K Linstrum, E Litton, E Lorenzi, J Marshall, D McAuley, A McGlothin, S McGuinness, B McVerry, S Montgomery, P Mouncey, S Murthy, A Nichol, R Parke, J Parker, K Rowan, A Sanil, M Santos, C Saunders, C Seymour, A Turner, F van de Veerdonk, B Venkatesh, R Zarychanski, S Berry, RJ Lewis, C McArthur, SA Webb, AC GordonFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.